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To the Editors:
As authors of a similar article,1 we read with great
interest the report by Koskivuo et al.,2 in the
December issue of the Annals of Surgical Oncology.
We enthusiastically support the basic rationale for
this paper and the two researched patient groups,
which have been correctly balanced for most of the
important prognostic factors, such as Breslow thick-
ness, ulceration status, and tumor site. However,
some other methodological and other points may not
have been entirely correctly addressed.
In the previous study fromour center,1 we compared
two patient groups that consisted of node-positive
patients. One group underwent wide local excision
(WLE) and developed a regional lymph node metas-
tasis for whichwe performed a therapeutic lymph node
dissection (TLND). The other group had a positive
sentinel node (SN) and underwent a completion lymph
node dissection (CLND). Recently we have updated
our follow-up information; the median follow-up time
is now 5 8 months for the TLND group and
5 1 months for the SN+CLND group.When survival
rates were calculated from the diagnosis date of the
primary tumor, there seemed to be a trend towards a
14%survival benefit for theCLNDgroup (P=0.065).
However, when patients with minimal SN tumor bur-
den (according to the Rotterdam criteria <0.1 mm in
maximum diameter3,4) were excluded, because their
prognosis is identical to SN-negative patients, this
survival benefit disappeared (P = 0.333). Treatment
(WLE followed by TLND versus SN followed by
CLND) was not an independent prognostic factor for
survival.1
The initial paper from our institute1 was already
scrutinized for its lack of follow-up balance between
the two groups (the WLE-only group versus the SN-
staged group), which is now 58 (+2) versus 51 (+14)
months. The present study2 has an even greater
misbalance in follow-up: a median of 7 4 months for
the WLE versus 16 for SN group. It stands to reason
to expect that the SN group will develop more
recurrences and deaths.
Even though the WLE group has a significantly
longer follow-up, there seems to be a critical mis-
balance in nodal disease between the two groups.
There were 72 nodal recurrences in the WLE group
(11.7%) versus 50 positive SNs (16.4%). This is even
without the nodal relapses (n = 5; 1.6%) in the SN
group.2 This suggests that not all positive sentinel
nodes will develop into palpable nodal disease.
The authors state that improved regional disease
control is an obvious therapeutic advantage of SN
staging and immediate CLND. This statement can
only be made in the context of a comparison of nodal
recurrence rates after SN+CLND versus those after
TLND. This comparison has not been made in the
present study. Instead the authors compare the 1.6%
nodal recurrences after SN+CLND with the 11.7%
of patients that undergo a TLND after WLE only.
This is obviously an incorrect comparison since the
lymph node dissection in one group has already been
performed and therefore this comparison does not
make sense.
Another important observation in light of another
recent publication from Sheri et al.5 in the October
edition of this same journal, but also in light of a
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study from our institute, is the rate and survival of
patients in the Starz I tumor burden (<0.3 mm)
category.6 The rate of Starz I patients was 9/49
(18%), which is virtually identical to the results from
our institute.3, 4 More importantly was the observa-
tion of a 100% overall survival rate from this group,
which is again a confirmation of the excellent survival
of patients with minimal SN tumor burden from
other series and recently from a multicenter experi-
ence presented at ECCO 14 in Barcelona in Septem-
ber 2007.3
Finally, we agree with the authors with regard to the
fact that SN staging is necessary to provide the optimal
treatment to melanoma patients. In the absence of
effective chemo- or immunotherapy, such treatments
need to be identified by the conduct of randomized
controlled trials for which SN status is a crucial
stratification. SN staging will have increasing compe-
tition however from ultrasound-guided fine-needle
aspiration cytology (FNAC), which may be able to
replace the current SN staging in most patients based
on a trial in 400 patients as reported in the Presidential
Session of the last ECCO meeting.7
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